AAIC 2026 A comparative effectiveness analysis of second-line diabetes medications in realworld registry (Danish registry) comparing GLP-1 RAs to other agents found a protective effect of GLP-1 RAs vs certain other second-line drugs over 5 years, though not against all comparators
Publisher | Google Scholor Sun H, Shu J, Tang J, Li Y, Qiu J, et al
Dose is 0.25mg
10.1007/s13410-020-00820-9 164
Does not contain sugar - The product uses low-energy sweeteners, such as maltitol, sorbitol, sucralose or acesulfame K, which contribute to reducing the calorific value of the diet
Statistical analysis The results obtained were subjected to the analysis of variance using the Statgraphics XVII program